ANAB | AnaptysBioNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history

$47.73
+$0.82 (+1.75%)

AnaptysBio (ANAB) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2018.

The 50 SMA has sat below the 200 on the daily since Sep 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the 4-hour, price sits below the 50 and the 200; on the weekly it is between the two.

Timeframe summary

Daily as of 3 Nov 16:00 ET

Price
below both $47.73 vs 50 $51.33 / 200 $56.51
Projection
No cross projected
Test
No active test
Last cross
Death cross 21 Sep 2026 ยท projected 11 bars out ยท tested 2 bars

Weekly as of 30 Oct 16:00 ET

Price
between the two $48.28 vs 50 $54.55 / 200 $30.89
Projection
No cross projected
Test
No active test
Last cross
Golden cross week of 8 Dec 2025 ยท projected 24 bars out

4-hour as of 3 Nov 16:00 ET

Price
below both $47.73 vs 50 $47.96 / 200 $54.89
Projection
No cross projected
Test
No active test
Last cross
Death cross 24 Jul 2026 ยท projected 12 bars out

Cross history

32
crosses on record since 2018
16 golden16 death
Full cross history โ†’
CrossedDirectionTimeframeProjectedCross test
21 Sep 2026Death moderatedaily11 bars out2 bar cross test
24 Jul 2026Death4-hour12 bars outNot tested
14 Jul 2026Golden4-hour26 bars out1 bar cross test
12 Jun 2026Death4-hour24 bars out5 bar cross test
week of 8 Dec 2025Golden moderateweekly24 bars outNot tested

About ANAB

ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$21.7M
4-hour coverageYes, since Oct 2025
History on recordSince 2018
SectorHealthcare
Cap bandsmall

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.